Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA6 | P23280 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9640746 | 0.82 | PTGS2 (0.36) | BCAT2ADRA1ADRD2HSD11B1ADRA2A | |
| SCHEMBL8106699 | 0.81 | LOX (0.47) | BCAT2ADRA1ALOXDRD2HSD11B1 | |
| Barbituric Acid SCHEMBL9641626 | 0.80 | TDP2 (0.38) | BCAT2ADRA1ADRD2ADRA2AADRA2C | |
| SCHEMBL745249 | 0.80 | ALDH1A1 (0.44) | GAAHTR6CA1CA2CA4 | |
| SCHEMBL29515914 | 0.80 | ALDH1A1 (0.44) | GAAHTR6CA1CA2CA4 | |
| SCHEMBL1682100 | 0.79 | GAA (0.50) | GAAHTR6CA1CA2CA4 | |
| SCHEMBL9641951 | 0.79 | ALDH1A1 (0.35) | ADRA1AGAAADRA2AADRA2CADRA1D | |
| SCHEMBL9641657 | 0.78 | ADRA1A (0.32) | ADRA1ALOXADRA2AADRA2CADRA1D | |
| SCHEMBL15461559 | 0.78 | CYP1A2 (0.45) | CA1CA2CA9L3MBTL1 | |
| SCHEMBL23874979 | 0.77 | TAAR1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0225478-B1 | IODONIUM YLIDE ANTIMICROBIAL COMPOUNDS | THE DOW CHEMICAL COMPANY (US) | 1990-05-16 | — | — | EP | claimed |
| WO-2025038395-A1 | BENZOPYRIDINONES AND BENZOPYRIMIDINONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022249006-A1 | USE OF 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022135591-A1 | ARYL OR HETEROARYL PYRIDONE OR PYRIMIDONE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2021249563-A1 | ARYL OR HETEROARYL PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2021-12-16 | — | — | WO | disclosed |
| WO-2021143693-A1 | ARYL OR HETEROARYL PYRIDONE OR PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 苏州泽璟生物制药股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| EP-3262057-B1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| WO-2006021805-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| EP-1613319-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. | 2004-12-16 | — | — | US | disclosed |
| WO-2004091613-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-5403859-A | PHENYLENE-CYCLIC ETHER COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-04-04 | — | — | US | disclosed |
| EP-0375404-B1 | Heterocyclic derivatives | ICI PLC (GB) | 1994-02-09 | — | — | EP | disclosed |
| US-5234950-A | Antiallergens, antiinflammatory agents; cardiovascular disorders, antiarthritic | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-10 | — | — | US | disclosed |
| US-5106407-A | Algicides, funcilides, bactericides | THE DOW CHEMICAL COMPANY (US) | 1992-04-21 | — | — | US | disclosed |
| US-5098930-A | Inhibitors of lipoxygenase for treatment of diseases mediated with leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-03-24 | — | — | US | disclosed |
| EP-0375404-A2 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | BCAT2 2245/4885ADRA1A 4196/4885LOX 2269/4885 |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | TFPI, F12, SPINT2 | BCAT2 297/4885ADRA1A 2765/4885LOX 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.